Testing StrataMGT for vulvar lichen sclerosus symptoms
Part of Women’s health & pregnancy clinical trials.
This study tests whether a new topical treatment, StrataMGT, can reduce symptoms of vulvar lichen sclerosus. It is for women with moderate to severe symptoms who are already using a stable topical prescription.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and 18 years or older.
- You have a confirmed diagnosis of vulvar lichen sclerosus by biopsy.
- You have moderate to severe LS symptoms (score of 10 or more on a special symptom questionnaire).
- You have been using a stable dose of a topical steroid or calcineurin inhibitor for at least 2 months.
- You do not have other serious skin conditions like lichen planus, psoriasis, or vulvar cancer.
- You do not have an active infection (bacterial or yeast) at screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares three treatments for vulvar lichen sclerosus: a steroid ointment, a non-steroid ointment, and platelet-rich plasma therapy. It aims to see which works best for managing symptoms and improving skin health.
This study tests the drug methotrexate as a treatment for severe vulvar lichen sclerosus that has not responded to strong steroid creams. It aims to see if methotrexate can reduce symptoms and prevent further scarring.
This study compares a new non-invasive treatment using radiofrequency energy to a standard steroid cream for women with vulvar lichen sclerosus. The goal is to see which works better for symptom relief.
This study compares two treatments—clobetasol steroid cream or a fractional CO2 laser—for women with vulvar lichen sclerosus who have not used steroid cream before. It looks at how inflammation changes after treatment.
This study tests whether a shot of concentrated healing cells from umbilical cord blood (called platelet-rich plasma) can help treat vulvar lichen sclerosus better than a placebo shot. It aims to find a new, safe option for women who are not helped by standard treatments.
This study tests if a new drug called nemolizumab can help reduce itch in women with lichen sclerosus (LS) in the genital area. Participants must have tried topical steroids before.
Hear when a new Vulvar Lichen Sclerosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.